The FDA approved an additional indication for Janssen Biotech’s Simponi Aria (golimumab), the company said.
The approval is for treatment of adults with psoriatic arthritis or ankylosing spondylitis.
The drug was approved in 2013 for treatment of rheumatoid arthritis.